EG-018 is a synthetic research chemical that has gained popularity among those looking to explore the world of designer drugs. However, when purchasing such substances online, caution should be exercised. The sellers and vendors offering EG-018 for sale online often raise significant concerns.
One of the primary issues with EG-018 research chemical sellers is the need for more regulation and oversight in the online marketplace. Many of these vendors operate in a legal gray area, exploiting loopholes in drug laws to sell these substances without adequate quality control or safety measures. This leaves buyers vulnerable to purchasing products that may be impure, adulterated, or contaminated, posing severe health risks.
Furthermore, the credibility of these sellers is often questionable. Since designer drugs like EG-018 are relatively new and constantly evolving, the knowledge and expertise of the vendors can be limited. This lack of understanding may lead to inaccurate product descriptions, dosage recommendations, and potential misinformation about the substance’s effects.
Another concern is the marketing tactics employed by some EG-018 sellers. They often advertise their products as “legal highs” or “research chemicals,” creating an illusion of safety. However, the legality of these substances can change rapidly, and individuals may unknowingly be breaking the law by purchasing or possessing them.
In addition to these concerns, there is also the issue of ethical responsibility. Selling research chemicals like EG-018 without adequate information on potential risks and proper usage guidelines can have severe consequences for unsuspecting buyers.
- 1 Summary
- 2 Legal status
- 3 FAQ
- 3.1 1. What is EG-018?
- 3.2 2. How does EG-018 work?
- 3.3 3. Is EG-018 legal?
- 3.4 4. What are the effects of EG-018?
- 3.5 5. Is EG-018 safe to use?
- 3.6 6. Where can I get EG-018?
- 3.7 7. Are there any known side effects of EG-018?
- 3.8 8. Can EG-018 be detected in drug tests?
- 3.9 9. Is there any legitimate research on EG-018?
- 4 References
EG-018 is a synthetic cannabinoid derived from carbazole, primarily distributed online as a designer drug. It functions as a partial agonist for both CB1 and CB2 receptors, exhibiting a relatively strong binding affinity while demonstrating limited effectiveness in triggering signaling responses.
|Chemical and physical data|
|Molar mass||391.514 g·mol−1|
|Legal status||CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Under Psychoactive Substances ActIllegal in Japan|
1. What is EG-018?
- EG-018 is a synthetic cannabinoid that belongs to the carbazole-based family. It is primarily known and sold as a designer drug in online markets.
2. How does EG-018 work?
- EG-018 acts as a partial agonist for both CB1 and CB2 cannabinoid receptors. It binds to these receptors with relatively high affinity but has limited efficacy in activating signaling responses.
3. Is EG-018 legal?
- The legal status of EG-018 varies by location and country. You must check your local laws and regulations regarding synthetic cannabinoids before considering their purchase or use.
4. What are the effects of EG-018?
- Due to limited research on EG-018, its specific effects on humans must be well-documented. It is essential to exercise caution and avoid its use until more information becomes available regarding its safety and potential risks.
5. Is EG-018 safe to use?
- The safety of EG-018 is not well-established. Designer drugs like EG-018 can have unpredictable and potentially harmful effects on users. A lack of clinical studies and safety data makes it risky to consume.
6. Where can I get EG-018?
- While EG-018 may be available from various online sources, it is crucial to note that purchasing synthetic cannabinoids from unverified or unregulated vendors can be dangerous. Always prioritize your safety and legality when considering any substance purchase.
7. Are there any known side effects of EG-018?
- Limited information is available regarding the side effects of EG-018. Given its classification as a synthetic cannabinoid, it may carry risks similar to other compounds in this category, such as anxiety, paranoia, and adverse physical effects.
8. Can EG-018 be detected in drug tests?
- EG-018 and other synthetic cannabinoids may not be part of standard drug tests. However, specialized tests can detect these substances. Always be aware of the potential legal and employment consequences of consuming such substances.
9. Is there any legitimate research on EG-018?
- Scientific research on EG-018 is limited, and most information available is anecdotal. Due to its status as a designer drug, it may be studied less extensively in a controlled research setting.
- “EG 018”. www.caymanchem.com.
- Mogler L, Franz F, Wilde M, Huppertz LM, Halter S, Angerer V, et al. (September 2018). “Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples”. Drug Testing and Analysis. 10 (9): 1417–1429. doi:10.1002/dta.2398. PMID 29726116.
- Banister SD, Connor M (August 2018). “The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution”. New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. Springer International Publishing. pp. 191–226. doi:10.1007/164_2018_144. ISBN 978-3-030-10561-7. PMID 30105473 – via Springer Link.
- Gaunitz F, Dahm P, Mogler L, Thomas A, Thevis M, Mercer-Chalmers-Bender K (June 2019). “In vitro metabolic profiling of synthetic cannabinoids by pooled human liver microsomes, cytochrome P450 isoenzymes, and Cunninghamella elegans and their detection in urine samples”. Analytical and Bioanalytical Chemistry. 411 (16): 3561–3579. doi:10.1007/s00216-019-01837-8. PMID 31183523. S2CID 184487406.
- Diao X, Carlier J, Zhu M, Huestis MA (July 2018). “Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry”. Forensic Toxicology. 36 (2): 304–312. doi:10.1007/s11419-018-0404-2. ISSN 1860-8973. S2CID 44196013.
- Gamage TF, Barrus DG, Kevin RC, Finlay DB, Lefever TW, Patel PR, et al. (June 2020). “In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018”. Pharmacology, Biochemistry, and Behavior. 193: 172918. doi:10.1016/j.pbb.2020.172918. PMC 7239729. PMID 32247816.
- “指定薬物を指定する省令が公布されました｜厚生労働省”. www.mhlw.go.jp (in Japanese). Ministry of Health, Labour and Welfare.